{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:16Z","timestamp":1787117116309,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The Kirsten rat sarcoma viral oncogene homolog\n                      <jats:sup>G12C<\/jats:sup>\n                      (KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      ) mutation is no longer an \u201celusive\u201d target, having become an important therapeutic target in non-small cell lung cancer (NSCLC). The approvals of sotorasib and adagrasib have significantly altered the second-line treatment algorithm. This systematic review critically evaluates and compares data from Phase III clinical trials and the mechanisms of resistance associated with these two inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The systematic review was registered in the PROSPERO database and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed, Scopus, and ClinicalTrials.gov were searched for phase III randomized controlled trials (RCTs) conducted between 2023 and 2026. The analysis included the CodeBreaK 200 and KRYSTAL-12 registration programs (including subanalyses), which evaluated monotherapy with sotorasib or adagrasib compared with docetaxel in patients with advanced NSCLC harboring the KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      mutation. The risk of bias was assessed using the Cochrane RoB 2.0 tool.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both inhibitors significantly prolonged the median progression-free survival (PFS) and increased the objective response rate (ORR) compared with chemotherapy. Adagrasib demonstrated promising intracranial efficacy but was associated with greater gastrointestinal toxicity and frequent dose reductions. Sotorasib was characterized by a better safety profile and more favorable quality-of-life outcomes for patients, although the assessment of its impact on overall survival (OS) was confounded by a high crossover rate in the registration trial. However, the rapid development of secondary mutations and bypass resistance mechanisms remains the main clinical limitation of both drugs when used as monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Sotorasib and adagrasib provide clinical benefit in advanced NSCLC with the KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      mutation, demonstrated improved clinical outcomes compared with docetaxel monotherapy. However, to overcome the barrier of inevitable biological resistance, it is crucial to seek new therapeutic approaches and intensively develop combination strategies based on these molecules, which supports the ongoing development of combination strategies in personalized oncology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261427962.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1916211","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:39:42Z","timestamp":1787114382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Julia","family":"Piekarz","sequence":"first","affiliation":[{"name":"Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Picheta","sequence":"additional","affiliation":[{"name":"Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Pobide\u0142","sequence":"additional","affiliation":[{"name":"Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gierulska","sequence":"additional","affiliation":[{"name":"Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"K\u0142odnicka","sequence":"additional","affiliation":[{"name":"Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Januszewski","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Szklener","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sk\u00f3rzewska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.4103\/ijc.IJC_52_21","article-title":"Evolving trends in lung cancer: Epidemiology, diagnosis, and management","volume":"59","author":"Deshpand","year":"2022","journal-title":"Indian J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.042","article-title":"Recurrence-free survival in patients with surgically resected non-small cell lung cancer: A systematic literature review and meta-analysis","volume":"165","author":"Rajaram","year":"2024","journal-title":"CHEST"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108618","article-title":"Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC","volume":"205","author":"Navani","year":"2025","journal-title":"Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083818","article-title":"The current roadmap of lung cancer biology, genomics and racial disparity","volume":"26","author":"Alsatari","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02030-7","article-title":"Targeting KRASG12C in non-small-cell lung cancer: Current standards and developments","volume":"84","author":"Torres-Jim\u00e9nez","year":"2024","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104228","article-title":"Niedrobnokom\u00f3rkowy rak p\u0142uc (NSCLC) wywo\u0142any mutacj\u0105 genu KRAS G12C","volume":"195","author":"Rosell","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf153","article-title":"KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape","volume":"30","author":"Frisch","year":"2025","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3210","article-title":"Allosteric regulation of switch-II domain controls KRAS oncogenicity","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302485120","article-title":"Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors","volume":"120","author":"Akkapeddi","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102957","article-title":"Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) \u2013 biology, clinical results and future directions","volume":"137","author":"Attili","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107886","article-title":"The next-generation KRAS inhibitors\u2026What comes after sotorasib and adagrasib","volume":"194","author":"Oya","year":"2024","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30163436","article-title":"Interaction mechanisms of KRAS G12C inhibitors (sotorasib and adagrasib) with human serum albumin: Insights from spectroscopic and molecular docking studies","volume":"30","author":"Qin","year":"2025","journal-title":"Molecules"},{"key":"B18","doi-asserted-by":"publisher","first-page":"OF4","DOI":"10.1158\/2159-8290.CD-NB2021-0362","article-title":"FDA approves first KRAS inhibitor: Sotorasib","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611715","article-title":"Targeted therapeutic options in early and metastatic NSCLC-overview","volume":"30","author":"G\u00e1lffy","year":"2024","journal-title":"Pathol Oncol Res POR"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1106","article-title":"Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer","volume":"19","author":"Guo","year":"2023","journal-title":"Future Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114204","article-title":"Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC","volume":"208","author":"Hochmair","year":"2024","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-97","article-title":"Is adagrasib just another sotorasib?\u2014or, should we differentiate their usage according to patients\u2019 clinical presentation","volume":"12","author":"Oya","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-026-01003-0","article-title":"Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases","volume":"33","author":"Bhattacharya","year":"2026","journal-title":"Cancer Gene Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"Langen","year":"2023","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108683","article-title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","volume":"207","author":"Dingemans","year":"2025","journal-title":"Lung Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107921","article-title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","volume":"196","author":"Waterhouse","year":"2024","journal-title":"Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S473368","article-title":"KRASG12C inhibitors in non-small cell lung cancer: A review","volume":"17","author":"Tang","year":"2024","journal-title":"OncoTargets Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ccell.2025.06.011","article-title":"KEAP1 and STK11\/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer","volume":"43","author":"Galan-Cobo","year":"2025","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050749","article-title":"KRAS-mutant lung cancer: Targeting molecular and immunologic pathways, therapeutic advantages and restrictions","volume":"12","author":"Karimi","year":"2023","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196826","article-title":"KRAS G12C mutation predicts improved survival in NSCLC patients receiving immunotherapy: Insights from a real-world cohort","volume":"14","author":"Ge\u00e7gel","year":"2025","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107960","article-title":"Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)","volume":"197","author":"Johnson","year":"2024","journal-title":"Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4023","article-title":"Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer","volume":"27","author":"Arbour","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00892","article-title":"Redefining available therapy in oncology accelerated approval decisions","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1142\/S0219720025500179","article-title":"Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer","volume":"23","author":"Wu","year":"2025","journal-title":"J Bioinform Comput Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.21037\/tlcr-2025-1-1431","article-title":"Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors","volume":"15","author":"Ozakinci","year":"2026","journal-title":"Transl Lung Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00040","article-title":"Single-agent divarasib in patients with KRAS G12C\u2013positive non\u2013small cell lung cancer: Long-term follow-up of a phase I study","volume":"43","author":"Sacher","year":"2025","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"TPS8656","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8656","article-title":"Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)","volume":"43","author":"Skoulidis","year":"2025","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:39:52Z","timestamp":1787114392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1916211"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1916211","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1916211"}}